Skip to main content

Table 2 The CYP2D6 genotype frequency

From: Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

 

Genotype

N = 279

Frequency (%)

EM/EM

*1/*2

44

15.8

n = 87 (31.2 %)

*1/*1

33

11.8

 

*2/*2

10

3.6

EM/IM

*1/*41

24

8.6

n = 43 (15.4 %)

*2/*41

10

3.6

 

*1/*10

7

2.5

 

*2/*10

2

0.7

EM/PM

*1/*4

51

18.3

n = 97 (34.8 %)

*2/*4

30

10.8

 

*1/*5

6

2.2

 

*1/*3

4

1.4

 

*2/*5

3

1.1

 

*1/*6

1

0.4

 

*2/*3

1

0.4

 

*2/*6

1

0.4

IM/IM

*41/*41

1

0.4

n = 3 (1.1 %)

*10/*10

1

0.4

 

*10/*41

1

0.4

IM/PM

*4/*41

6

2.2

n = 11 (3.9 %)

*4/*10

3

1.1

 

*4/*17

1

0.4

 

*5/*41

1

0.4

PM/PM

*4/*4

15

5.4

n = 20 (7.2 %)

*3/*4

2

0.7

 

*4/*5

2

0.7

 

*4/*6

1

0.4

UM

*1/*2 (xN)

10

3.6

n = 18 (6.5 %)

*1/*1 (xN)

5

1.8

 

*2/*2 (xN)

3

1.1

  1. EM extensive-metabolizer, IM intermediate-metabolizer, PM poor-metabolizer, UM ultra-rapid-metabolizer
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us